OverviewDosage GuideSide EffectsProtocolResultsWeight LossClinical TrialsInjection GuideGLP-3How to GetCostFDA ApprovalAvailabilityTelehealthLiver FatMuscle LossWhere to Buy
Tirzepatide Protocol Guide
A structured protocol for using Tirzepatide: cycle length, administration timing, stacking considerations, and monitoring.
Protocol Overview
Recommended Cycle Length
12–52 weeks (chronic use)
Dosing Frequency
Once weekly
Administration Route
Subcutaneous injection (abdomen, thigh, upper arm)
Titration Required
Yes — see schedule
Week-by-Week Titration Protocol
1
Week
2.5mg
Starting dose — monitor for side effects
5
Week
5mg
Increase if previous dose was well-tolerated
9
Week
7.5mg
Increase if previous dose was well-tolerated
13
Week
10mg
Increase if previous dose was well-tolerated
17
Week
12.5mg
Increase if previous dose was well-tolerated
21
Week
15mg
Maximum / maintenance dose
Stacking & Combination Protocols
Important: Stacking Tirzepatide with other active compounds significantly increases the complexity of managing side effects and monitoring. Always consult a qualified healthcare provider before combining compounds.
Commonly Discussed Combinations
Cagrilintide
Research only — no approved combination existsAmylin analogue — Cagrisema (cagrilintide + semaglutide) trials show additive satiety effects. In theory, combining with Tirzepatide could further enhance weight loss through complementary mechanisms.
Synergy: High potential
MOTS-c
Research onlyMitochondrial-derived peptide that may enhance metabolic efficiency and fat oxidation. Believed to complement GLP-1 class drugs by addressing insulin resistance at the cellular level.
Synergy: Theoretical
CJC-1295 / Ipamorelin
Anecdotal onlyGrowth hormone secretagogues. Sometimes used alongside weight-loss peptides for lean mass preservation during aggressive caloric restriction. No clinical data on combination with Tirzepatide.
Synergy: Low / off-protocol
Do NOT Stack With
✗
Other GLP-1 agonists (semaglutide, tirzepatide)
Redundant mechanism, significantly elevated GI side effect risk, no clinical rationale
✗
Other GLP-1/GIP dual or triple agonists
Same receptor targets — additive side effects without additive benefit
✗
Insulin (without medical supervision)
Hypoglycemia risk — if diabetic and on insulin, dose reduction is required under medical guidance
Related Peptides
retatrutide— commonly compared / discussed alongside Tirzepatide
Learn more →semaglutide— commonly compared / discussed alongside Tirzepatide
Learn more →ipamorelin— commonly compared / discussed alongside Tirzepatide
Learn more →Monitoring While on Protocol
- ✓Track body weight weekly
- ✓Monitor blood glucose if diabetic or pre-diabetic
- ✓Check lipid panel and liver enzymes at baseline and every 3 months
- ✓Document side effects and dose response in a log
- ✓Schedule follow-up with prescribing provider every 4–8 weeks initially
Exploring Retatrutide Access?
See how patients are accessing retatrutide through physician-supervised telehealth and compounding pharmacies.
Not FDA approved. Access requires physician oversight.
Affiliate links — we may earn a commission at no cost to you.
Medical Disclaimer: This protocol guide is for informational purposes only and is based on available research. It does not constitute medical advice. Work with a licensed healthcare provider to design and monitor your peptide protocol.